New weapon against tough cancers enters human testing

This is the first human study of an experimental drug called DM919 for people with advanced solid tumors that have stopped responding to standard treatments. Researchers want to find safe doses of DM919 when given alone and when combined with another cancer drug (pembrolizumab), and see which types of cancer might respond. About 160 adults with various advanced cancers will receive the drug through an IV and be closely monitored for safety and early signs of effectiveness.